Table 2.
Prevalence of the use of pharmaceutical agents in patients with EOCRC and controls using eXtreme Gradient Boosting from data covering the period 2001-2019.
| ATCa class | ATC description | Prevalence of use in cases, n (%) | Prevalence of use in controls, n (%) | Rate of runs in which an association with CRCb was observedc (%) | Rate of runs with a global SHAPd value ≥97.5% of the distributione (%) |
| c07aa05 | Propranolol | 42 (4.5) | 228 (2.4) | 70 | 5 |
| c09aa02 | Enalapril | 44 (4.7) | 161 (2.8) | 60 | 3 |
| n05cm09 | Valerian | 47 (5) | 291 (3.1) | 58 | 2 |
| n06ab05 | Paroxetine | 15 (1.6) | 376 (4) | 54 | 10 |
| c10aa01 | Simvastatin | 99 (10.5) | 724 (7.7) | 50 | 4 |
| a10ba02 | Metformin | 40 (4.3) | 234 (2.5) | 46 | 2 |
| d04aa13 | Dimetindene | 67 (7.1) | 906 (9.6) | 40 | 1 |
| s01ca01 | Dexamethansone | 175 (18.6) | 1986 (21.1) | 36 | 3 |
| d07ac13 | Mometasone | 103 (10.9) | 1249 (13.3) | 32 | 1 |
| d11ax18 | Diclofenac | 86 (9.1) | 672 (7.1) | 30 | 1 |
| a02ba03 | Famotidine | 161 (17.1) | 1381 (14.7) | 28 | 1 |
| s01aa01 | Chloramphenicol | 301 (32) | 2782 (29.6) | 24 | 2 |
| j01ce02 | Phenoxymethylpenicillin | 335 (35.6) | 3443 (36.6) | 20 | 1 |
| r01ba52 | Pseuroephedrine, combination | 243 (25.8) | 2631 (28) | 20 | 1 |
| b03ad01 | Ferrous amino acid complex | 174 (18.5) | 1590 (16.9) | 16 | 1 |
| g01aa10 | Clindamycin | 79 (8.4) | 685 (7.3) | 10 | 1 |
| r03ac03 | Terbutaline | 51 (5.4) | 451 (4.8) | 2 | 1 |
aATC: Anatomical Therapeutic Chemical classification system.
bCRC: colorectal cancer.
cBased on global SHAP values calculated for each of 50 runs. A global SHAP value >0 for a given feature was considered evidence for an association with the outcome.
dSHAP: Shapley additive explanation.
eConsidering each of the 50 different global SHAP values distributions individually.